Opus Genetics (IRD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Opus Genetics (IRD) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.54 of bullish evidence against -0.24 bearish.

Opus Genetics last closed at $4.41, +0.68% on the session.

Against the IVW growth benchmark the position is +0.84% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

1 graded prediction for IRD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Opus Genetics in the 99th percentile on return on equity, where 100 is best.

Opus Genetics is classified under Health Care / Biotechnology, with a market capitalisation of $364.40M.

StockMap tracks Opus Genetics as the 199th largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Opus Genetics ranks 183rd of 377 in the group, against a group median of -0.21.